FROM IDEAS TO COMPANIES

OCTALFA is active and involved in supporting entrepreneurship in France. Its purpose is to promote academic and industrial research in the healthcare sector. Its missions are to identify inventions and expertises that will benefit to patients, coordinate research and feasibility studies prior to the inception of the company, define its strategy, set up the management and fund R&D until the market introduction of products or signing of structuring partnerships.

OCTALFA therefore supports companies until they achieve profitability, are sold or receive backing from an industrial or financial organisation.

OUR APPROACH

IDENTIFICATION

We identify new projects, assess their
feasibility before implementing the strategy
and the economic model.

VALIDATION

We validate the project with the inventor partners.

FUNDING

We fund companies created with a long-term vision.

MANAGEMENT

We define strategy, then structure,
grow and manage companies created.

 DEVELOPED PROJECTS

  • ORPHELIA Pharma

    SINCE 2015
    ORPHELIA Pharma is a pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases.

  • Mathym

    INCEPTED IN 2013
    Nanotechnology company dedicated to the development, manufacturing and commercialization of innovative colloidal solutions

  • OREGA Biotech

    INCEPTED IN 2010
    Biotechnology company dedicated to the research and development of novel antibodies for cancer immunotherapy

  • Alizé Pharma 3

    SINCE 2014
    Biopharmaceutical company developing innovative peptides for the treatment of osteoporosis and certain bone diseases

  • MILLENDO THERAPEUTICS

    Millendo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases.

  • ALIZÉ PHARMA

    SINCE 2007
    Clinical-stage biopharmaceutical company developing AZP-531, an analog of unacylated ghrelin for the treatment of Prader-Willi Syndrome and type 2 Diabetes. Acquired mainly by Millendo Therapeutics in 2017.

  • Nightswapping

    SINCE 2014
    Startup company developing novel collaborative tourism tools

  • JUVISE Pharmaceuticals

    FROM 2011 TO 2017
    Pharmaceutical company marketing products to treat psychiatric, inflammatory and respiratory diseases.

 NEWS PROJECTS

  • ORPHELIA PHARMA

    Strengthens its capital base and accelerates its development

  • Merry Christmas and Happy New year 2018

    initiative OCTALFA wishes you a Merry Christmas and a Happy New Year 2018

  • Millendo Therapeutics acquires Alizé Pharma

    The clinical-stage company focused on novel treatments for endocrine diseases will develop Alizé’s livoletide (AZP-531) for PWS.

  • Mathym launches filyxio®, a radiopacifying nano-dispersion made from ytterbium trifluoride (YbF3)

    Mathym SAS, a company specialized in the development, manufacturing and commercialization of nano-dispersions dedicated to biomedical applications, announces today the complete implementation of its first manufacturing line and the beginning of commercialization of filyxio®.

  • SIOP 2017

    Jeremy Bastid will attend the SIOP (Société Internationale d’Oncologie Pédiatrique) Congress in Washington, october 12-15.

  • Meet us at Bio Europe 2017 in Berlin

    Jeremy Bastid will attend the Bio-Europe event to be held in Berlin (Germany), november 6-8.

  • OREGA Biotech’s interleukin-17 patent to be granted in the US

    Receipt of a Notice of Allowance from USPTO for a strategic patent application related to OREGA’s IL-17 program

  • IL-17B program to be presented at AACR 2017

    OREGA will present latest in vivo data of its IL-17B program on April 3 at the upcoming AACR annual conference to be held in Washington DC